Hutchmed licenses KRAS-EGFR antibody-conjugate therapy from GSK
Hutchmed (China) Limited announced an exclusive licensing agreement with GSK covering the KRAS-EGFR antibody conjugate cancer therapy, including HMPL-A830.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.